Evaluation of Probiotic (KidiLact) effect on Headache Symptoms in Children aged 6 to 15 years with Migraine, who treated with Sodium Valproate Dependent

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200608047689N1

Enrollment

Registered

2020-11-28

Start date

2020-11-16

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine without aura. Migraine without aura

Interventions

Intervention 1: Intervention group: Patients will receive 2 sachets of 1 gram probiotic for 4 months. The supplement constituents are as follows: Lactobacillus Casei, Lactobacillus Rhamnosus, Streptoc

Eligibility

Sex/Gender

All

Age

6 Years to 15 Years

Inclusion criteria

Inclusion criteria: The diagnosis of Migraine for patients Using Sodium Valproate Age range between 6-15 years

Exclusion criteria

Exclusion criteria: Intestinal absorption and anatomic disorders Underlying problems such as Fanconi, Malabsorbtion, and Metabolic Disorders Intolerance to Sodium Valproate Gastrointestinal Problems The occurrence of complications of Sodium Valproate Unwillingness to Participate in this study Antibiotic therapy Using Probiotic or supplements consisting Probiotic effects in less than 2 months from initiation of the study

Design outcomes

Primary

Measure	Time frame
The severity of Migraine. Timepoint: Assessing the severity of Migraine before the intervention and 2, and 4 months after the intervention. Method of measurement: MIDAS scoring criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Bidabadi

Rasht University of Medical Sciences

bidabadi@mail.com+98 13 3372 9104

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026